Related Experiment Video

Updated: May 25, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies

Ramon Andrade de Mello1, Alessandro de Vasconcelos, Ronaldo A Ribeiro

  • 1Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-079, Porto, Portugal. ramonmello@med.up.pt

Recent Patents on DNA & Gene Sequences
|January 14, 2012
PubMed

Insights

New breast cancer treatments targeting HER2 resistance are emerging. Recent patents explore therapies for p95HER2 fragments, offering hope against trastuzumab resistance in advanced breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Breast cancer affects over 1.3 million globally, a leading cause of cancer death in women.
  • Hormone receptors and human epidermal growth factor receptor 2 (HER2) are key molecular targets.
  • Trastuzumab is a primary therapy for HER2-positive breast cancer but faces resistance.

Purpose of the Study:

  • To review recent patents concerning HER2 and p95HER2 fragments in breast cancer treatment.
  • To highlight therapeutic strategies addressing trastuzumab resistance mediated by p95HER2.

Main Methods:

  • Review of recent patent literature.
  • Analysis of therapeutic targets including HER2 and its fragments.
  • Discussion of emerging drug candidates and resistance mechanisms.

Main Results:

  • Identification of p95HER2 fragments as a mechanism of trastuzumab resistance.
  • Emergence of novel therapeutic agents, such as lapatinib, and others in patent filings.
  • Focus on targeted therapies addressing specific molecular alterations in breast cancer.

Conclusions:

  • Recent patents indicate promising alternative therapeutic options for breast cancer.
  • Targeting HER2 and its fragments like p95HER2 is crucial for overcoming treatment resistance.
  • Continued research and patenting activity are vital for advancing breast cancer management.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...